- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02424461
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection (PROSTASHORT)
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection Due to Fluoroquinolones Susceptible Bacteria: a Multicentre, Non-inferiority, Double Blind, Randomized Placebo-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study is a multicentre, non-inferiority, double blind, randomized placebo-controlled trial of treatment duration for male urinary tract infection (UTI) due to fluoroquinolones susceptible bacteria. Specifically, 284 men with a UTI will be randomized to 7 vs. 14 days of antimicrobial treatment. The primary outcome is resolution of fever, sterile urine analysis 4 weeks after completion of antimicrobial therapy and no antibiotic therapy active against the bacterial strain responsible for the UTI within the 4 week period following antimicrobial therapy. Secondary outcomes include the intestinal carriage of antimicrobial-resistant Gram-negative bacilli at the end of treatment, the incidence and severity of adverse drug events and the recurrent UTI within the treatment period and 4 weeks and 12 weeks of completing active study medication.
Currently, the optimal treatment duration for male UTI is unknown. Only one randomized study showed no difference in outcomes, in patients treated with ciprofloxacin during 14 vs. 28 days. However, this study was underpowered and included patient in a single center. Current treatment guidelines are not consensual and recommend treating men with UTI for 7 to 4 or 6 weeks. Shorter durations may expose patients to recurrence when longer duration may be associated with increase in Clostridium difficile infection and antimicrobial resistance. Longer-duration treatment is also more costly and inconvenient to patients. Thus, since longer-duration treatment is associated with some adverse outcomes, in order to justify longer-duration treatment thee must be some clinically significant benefit to the extended treatment.
The proposed randomized placebo-controlled trial will test the hypothesis that 7 days of antimicrobial treatment is non-inferior for the resolution of fever and microbiological success when compared to 14 days of treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Matthieu Lafaurie, MD
- Phone Number: +33 1 42 02 66 45
- Email: matthieu.lafaurie@sls.ap-hop-paris.fr
Study Locations
-
-
-
Paris, France, 75010
- Recruiting
- Saint Louis Hospital
-
Contact:
- Matthieu Lafaurie, MD
- Phone Number: +33 1 42 02 66 45
- Email: matthieu.lafaurie@sls.ap-hop-paris.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male gender, 18 years and older
New-onset of the following criteria:
- Temperature ≥38° Celsius or <36° Celsius (or at least once in the 3 previous days), AND
- at least one of following symptoms/findings: dysuria, urinary frequency, urgency, urinary burning, hematuria, perineal pain, supra-pubic pain or urinary retention, painful prostate (digital prostate examination)
- Leucocyturia ≥ 10/ mm3
- Urinary signs/symptoms within the 3 previous months
- Urinary culture yielding a single pathogen, at least10^3 colony-forming unit (CFU)/ml, susceptible to nalidixic acid, ofloxacine and ceftriaxone.
- Oral route for study drug
- Normal Ultrasound prostatic findings (no abscess and post-void residual urine volume < 100 ml).
Exclusion Criteria:
- Septic shock
- Admission to the hospital (for > 48 h) at the time of diagnosis
- Treatment for UTI in the past year
- Urinary catheter
- Severe disease with strong probability of death within 3 months
- Severe allergy or contraindication to fluoroquinolones or beta-lactams
- Not able to give informed consent
- Antimicrobial therapy with fluoroquinolone or aminoglycoside in the 3 previous days
- Neutropenia (neutrophils count < 500/mm3)
- Renal insufficiency (creatinin clearance ≤ 20 ml/min)
- Glucose - 6 - Phosphate - Dehydrogenase deficiency
- Significant cognitive disorders
- Uncontrolled epilepsy
- History of tendinitis
- Elevated liver enzyme levels (aspartate aminotransferase (ASAT), Alanine Amino Transferase (ALAT) ≥ 5 upper limit of normal range (ULN))
- Myasthenia
- Significant psychiatric disorders
- Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- Patient under guardianship patient, guardianship or without social security cover
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 7 day-antimicrobial treatment
Ceftriaxone : 1 injection 1 g per day for 2 days Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days Placebo of ofloxacine for 7 days |
1 injection 1 g per day for 2 days
400 mg/jour (200 mg/ jour in case of renal failure) for seven days
400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
|
Active Comparator: 14-day antimicrobial treatment
Ceftriaxone : 1 injection 1 g per day for 2 days Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days |
1 injection 1 g per day for 2 days
400 mg/jour (200 mg/ jour in case of renal failure) for seven days
400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
Placebo of ofloxacine for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success defined by resolution of fever
Time Frame: day 42
|
Defined by 3 criteria that should be fulfilled:
|
day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intestinal carriage of antimicrobial-resistant Gram-negative bacilli
Time Frame: 4 and 12 weeks
|
intestinal carriage of antimicrobial-resistant Gram-negative bacilli at the end of treatment and 4 and 12 weeks after completing study medication, as compared to a baseline sample taken before treatment
|
4 and 12 weeks
|
Incidence and severity of adverse drug events
Time Frame: 4 and 12 weeks
|
the incidence and severity of adverse drug events within the treatment period and in the 4 and 12 weeks after completing study medication
|
4 and 12 weeks
|
Recurrent UTI
Time Frame: 4 and 12 weeks
|
Recurrent UTI within 4 weeks and 12 weeks of completing active study medication
|
4 and 12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Disease Attributes
- Infections
- Communicable Diseases
- Urinary Tract Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Ceftriaxone
- Levofloxacin
- Ofloxacin
Other Study ID Numbers
- P120116
- AOM12268 (Other Grant/Funding Number: France: Ministry of Health (PHRC))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Male Urinary Tract Infection
-
Wuerzburg University HospitalUniversity of Bristol; University of Georgia; LMU Klinikum; University of Wuerzburg and other collaboratorsRecruitingMedication Adherence | Antibiotic Resistant Infection | Urinary Tract Infection Lower Acute | Urinary Tract Infection Bacterial | Cystitis AcuteGermany
-
Nader ShaikhNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedUrinary Tract Infection | Acute Urinary Tract InfectionUnited States
-
Spero TherapeuticsGlaxoSmithKlineRecruitingUrinary Tract Infection | Acute PyelonephritisMoldova, Republic of, Georgia, United States, Serbia, Bulgaria, Romania, South Africa
-
Meiji Seika Pharma Co., Ltd.RecruitingAcute Pyelonephritis | Complicated Urinary Tract InfectionEstonia
-
WockhardtMedpace, Inc.RecruitingAcute Pyelonephritis | Complicated Urinary Tract InfectionUnited States, China, India, Lithuania, Mexico, Peru, Poland, Bulgaria, Estonia
-
WockhardtNot yet recruitingAcute Pyelonephritis | Complicated Urinary Tract Infection
-
Iterum Therapeutics, International LimitedAvailableAcute Pyelonephritis | Complicated Urinary Tract Infection
-
University of Southern DenmarkCompleted
-
Impatients N.V. trading as myTomorrowsInmunotek S.L.No longer availableUrinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract InfectionCzechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
-
Nabriva Therapeutics AGMedpace, Inc.CompletedAcute Pyelonephritis | Urinary Tract Infection Complicated | Urinary Tract Infection SymptomaticPoland, Ukraine, Belarus, Bulgaria, Romania, Greece, United States, Russian Federation, Hungary, Lithuania, Slovakia, Czechia, Latvia, Croatia, Georgia, Estonia
Clinical Trials on Ceftriaxone
-
Baxter Healthcare CorporationHalozyme TherapeuticsCompleted
-
National Institute of Neurological Disorders and...CompletedLyme Disease | Lyme NeuroborreliosisUnited States
-
Yale UniversityStanley Medical Research InstituteTerminated
-
Association Pour La Promotion A Tours De La Reanimation...UnknownSepsis | Septic Shock | Severe SepsisFrance
-
University Medical Centre LjubljanaUnknown
-
Nantes University HospitalCompletedMeningitis | Neurological InfectionsFrance
-
Makerere UniversityCompleted
-
Fundación Pública Andaluza para la gestión de la...CompletedInfectious EndocarditisSpain
-
The Grant Medical College & Sir J.J. Group of HospitalsRecruitingSurgical Wound Infection | Surgical Site InfectionIndia
-
University of RochesterCompleted